Triptophenolide Improves Rheumatoid Arthritis and Progression by Inducing Macrophage Toxicity

Area of Science:

• Immunology
• Pharmacology
• Rheumatology

Background:

• Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint damage.
• Current treatments for RA have limitations, necessitating the exploration of novel therapeutic agents.
• Triptophenolide (TRI) is a compound with potential anti-inflammatory properties.

Purpose of the Study:

• To elucidate the mechanism of triptophenolide (TRI) in combating rheumatoid arthritis (RA).
• To evaluate the efficacy of TRI in an animal model of RA.
• To identify the key signaling pathways modulated by TRI in RA treatment.

Main Methods:

• Network pharmacology analysis was employed to predict the targets of TRI.
• In vivo experiments using a mouse model of RA were conducted.
• Histopathological analysis was performed to assess tissue inflammation and injury.

Main Results:

• Network pharmacology identified TRI's association with multiple inflammation-related signaling proteins.
• TRI administration significantly suppressed RA development in mice.
• TRI treatment reduced tissue inflammation and ameliorated synovial injury.
• TRI inhibited pyroptosis, a crucial pathway in RA pathogenesis.

Conclusions:

• Triptophenolide (TRI) demonstrates significant therapeutic potential for rheumatoid arthritis (RA).
• TRI exerts its anti-RA effects through modulation of multiple signaling pathways, including the inhibition of pyroptosis.
• Targeting pyroptosis represents a promising therapeutic strategy for RA management.